273 related articles for article (PubMed ID: 32500744)
1. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
Petrakis V; Panagopoulos P; Papanas N
Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin: a novel lipoglycopeptide antibacterial.
Pope SD; Roecker AM
Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of clinical evidence for dalbavancin].
Rodríguez-Pardo D
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
[TBL] [Abstract][Full Text] [Related]
4. The role of dalbavancin in skin and soft tissue infections.
Bassetti M; Peghin M; Carnelutti A; Righi E
Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
7. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin: a review.
Scheinfeld N
Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis.
Pantel A; Nachar O; Boudet A; Loubet P; Schuldiner S; Cellier N; Sotto A; Dunyach-Remy C; Lavigne JP
J Antimicrob Chemother; 2021 Jul; 76(8):2057-2060. PubMed ID: 33842980
[TBL] [Abstract][Full Text] [Related]
13. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
Kim A; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
15. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin: a new lipoglycopeptide antibiotic.
Bailey J; Summers KM
Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
[TBL] [Abstract][Full Text] [Related]
17. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin for the treatment of paediatric infectious diseases.
Esposito S; Bianchini S
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1895-1901. PubMed ID: 27562407
[TBL] [Abstract][Full Text] [Related]
20. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
